Drilldown: Medicines

None (1) · 3-MMC (1) · Butorphanol (1) · Butylone (1) · Cathinone (1) · Codeine (2) · Dextropropoxyphene (1) · Dihydrocodeine (1) · Ephylone (1) · Ethcathinone (1) · Ethylmorphine (1) · Ethylone (1) · Fentanyl (1) · Hexedrone (1) · Hydrocodone (1) · Hydromorphone (1) · Levorphanol (1) · Meperidine (1) · Mephedrone (1) · Methcathinone (1) · Methylone (1) · Mexedrone (1) · N-Ethylhexedrone (1) · N-Ethylpentedrone (1) · Nalbuphine (1) · Oxymorphone (1) · Papaverine (1) · Pentazocine (1) · Pentedrone (1) · Tapentadol (1)

None (19) · (multiple, generic dominant) (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Duragesic (1) · Nubain (1) · Nucynta (1) · Nuplazid (1) · Opana (1) · Stadol (1) · Talwin (1) · Vicodin (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

Cathinone analogue; monoamine reuptake inhibitor (2) · Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · Monoamine releasing agent (4) · Monoamine releasing agent; active ingredient in khat (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · Norepinephrine and dopamine releasing agent (1) · Norepinephrine/dopamine releasing agent (1) · Norepinephrine/dopamine reuptake inhibitor (1) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent mu-opioid receptor agonist (3) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · Selective inverse agonist at 5HT2A receptors with weaker activity at 5HT2C. Has no significant dopamine D2 affinity, unique among approved antipsychotics. Inverse agonism (rather than antagonism) reduces constitutive 5HT2A receptor activity below baseline. (1) · Serotonin releasing agent; monoamine reuptake inhibitor (1) · Serotonin/norepinephrine/dopamine releasing agent (3)

None (29) · Hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Investigational for psychosis in other dementias and as augmentation for depression. (1) · Mild to moderate pain; cough suppression (low-dose). (1)

None (29) · 34 mg PO once daily (1) · Adult: 15–60 mg every 4 hours as needed. (1)

None (29) · 10 mg, 34 mg capsules/tablets (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (29) · 34 mg/d (1) · 360 mg/day (1)

None (29) · Oral (1) · PO (only formulation marketed in the US). (1)

None (29) · 30–60 min (PO) (1) · Benefit over weeks of dosing (1)

None (29) · 4–6 hours (1) · Daily dosing (1)

None (29) · 2.5–3 hours (1) · ~57 hours (parent), ~200 h (active metabolite) (1)

None (29) · Not characterized; oral dosing once daily (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (29) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Limited data; avoid (1)

None (29) · Rx. FDA black-box warning for increased mortality in elderly patients with dementia-related psychosis (class warning shared with all antipsychotics) (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)